Aspira Women's Health (AWH) Investor Day 2024 summary

ARPA-H Award and Strategic Funding

• Secured $10 million non-dilutive ARPA-H Launchpad funding to accelerate development and commercialization of a non-invasive, AI-powered endometriosis diagnostic, with a two-year commercial launch goal and milestone-based payments over 24 months.

• Funding supports molecular lab buildout, R&D team expansion, and infrastructure benefiting both endometriosis (ENDOinform) and ovarian cancer (OVAinform) pipelines, including collaborations with Dana Farber Cancer Institute.

• ARPA-H program provides mentorship, regulatory, manufacturing, and reimbursement support, leveraging a robust network and accelerator resources.

• Recognition as a Launchpad awardee validates operational excellence and commercialization capabilities.

• Milestone-based funding structure ensures disciplined execution, with 60% of payments tied to early deliverables before prototype completion.

Product Development and Pipeline Progress

• OvaWatch and OvaWatch+ are on-market AI-powered blood tests for ovarian cancer risk assessment, with over 200,000 orders and New York State approval.

• OvaWatch demonstrated >99% negative predictive value and potential to reduce unnecessary surgeries by up to 62%, validated in large-scale, multi-site studies.

• OvaInform/OVAinform, the next-gen ovarian cancer test, will combine proprietary protein biomarkers and licensed microRNAs, aiming for best-in-class diagnostic performance and early-stage detection.

• EndoInform/ENDOinform, the multi-omic endometriosis diagnostic, integrates protein and microRNA biomarkers for early, non-invasive detection and longitudinal monitoring, advancing with ARPA-H support.

• Both OvaInform and EndoInform leverage shared infrastructure, AI expertise, and clinical partnerships, with parallel development timelines.

Market Opportunity and Commercialization

• Combined ovarian cancer and endometriosis diagnostics represent a potential $1 billion+ annual revenue opportunity, with OvaSuite tests priced at $897 per test and broad payer coverage.

• Addressable market includes 1.2–1.5 million women with adnexal masses and 6.5 million women affected by endometriosis in the US.

• Portfolio simplification and full launch of OvaWatch with longitudinal monitoring expand market reach.

• Existing reimbursement under Medicare and commercial/state plans, plus proven adoption strategies, position the company ahead of competitors.

• Ongoing buildout of commercial leadership and R&D capacity to support rapid scaling and execution.